Merit Health

“We are very grateful to FW Capital for their ongoing support. This investment will allow us to further the ambition of the cell and gene therapy industry to bring innovative new medicines to patients as quickly as possible.”

Matthew McGrady, Merit Health Finance Director

Specialist healthcare facilities firm Merit Health Ltd secured a £2m investment from FW Capital’s Tees Valley Catalyst Fund to enable it to fulfil a new £66m contract. The investment is the largest amount available from the TVCF.

Formed in 2020, the North East-based company used the funding fulfil its bond requirements for a contract to design, build and fit out a CAR-T Cell Manufacturing facility, also cited in Stevenage, this time for US organisation, Autolus, in association with developers, Reef Group.

The funding represented the second time FW Capital has supported Merit Holdings, following on from a previous TVCF investment in 2015. The funding has helped secure nearly 200 jobs at the business.

The Tees Valley Catalyst Fund closed to new applications on 31st March 2023.